BRPI0812768A2 - Igf para o tratamento de síndrome de rett e transtornos sinápticos. - Google Patents

Igf para o tratamento de síndrome de rett e transtornos sinápticos.

Info

Publication number
BRPI0812768A2
BRPI0812768A2 BRPI0812768-9A2A BRPI0812768A BRPI0812768A2 BR PI0812768 A2 BRPI0812768 A2 BR PI0812768A2 BR PI0812768 A BRPI0812768 A BR PI0812768A BR PI0812768 A2 BRPI0812768 A2 BR PI0812768A2
Authority
BR
Brazil
Prior art keywords
igf
treatment
rett syndrome
synaptic
disorders
Prior art date
Application number
BRPI0812768-9A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Miriganka Sur
Daniela Tropea
Emanuela Giacometti
Rudolf Jaenisch
Nathan R Wilson
Original Assignee
Massachusetts Inst Technology
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Whitehead Biomedical Inst filed Critical Massachusetts Inst Technology
Publication of BRPI0812768A2 publication Critical patent/BRPI0812768A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0812768-9A2A 2007-06-08 2008-06-06 Igf para o tratamento de síndrome de rett e transtornos sinápticos. BRPI0812768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93373807P 2007-06-08 2007-06-08
PCT/US2008/007107 WO2008153929A1 (en) 2007-06-08 2008-06-06 Igf for the treatment of rett syndrome and synaptic disorders

Publications (1)

Publication Number Publication Date
BRPI0812768A2 true BRPI0812768A2 (pt) 2014-12-02

Family

ID=39891784

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812768-9A2A BRPI0812768A2 (pt) 2007-06-08 2008-06-06 Igf para o tratamento de síndrome de rett e transtornos sinápticos.

Country Status (8)

Country Link
US (2) US7994127B2 (enExample)
EP (1) EP2164509A1 (enExample)
JP (1) JP2010529128A (enExample)
CN (1) CN101820896A (enExample)
AU (1) AU2008262387A1 (enExample)
BR (1) BRPI0812768A2 (enExample)
CA (1) CA2689549A1 (enExample)
WO (1) WO2008153929A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150039211A (ko) 2004-08-23 2015-04-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2650140A1 (en) * 2006-04-14 2007-10-25 Mriganka Sur Identifying and modulating molecular pathways that mediate nervous system plasticity
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
JP2012515202A (ja) 2009-01-16 2012-07-05 マサチューセッツ インスティテュート オブ テクノロジー 自閉症圏障害の診断および処置
ES2617309T3 (es) 2010-05-17 2017-06-16 Icahn School Of Medicine At Mount Sinai Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
LT2667715T (lt) * 2011-01-27 2017-11-10 Neuren Pharmaceuticals Limited Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį
CA3078334C (en) * 2011-04-01 2022-08-09 Mannkind Corporation Blister package for pharmaceutical cartridges
EP2734634B1 (en) * 2011-07-22 2019-08-21 The University of Chicago Igf-1 for use in the treatment of migraine
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
BR112015012506A2 (pt) * 2012-11-28 2017-07-11 Neuren Pharmaceuticals Ltd tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
ES2495266B8 (es) * 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
MX2017003892A (es) 2014-09-25 2018-01-30 Cold Spring Harbor Laboratory Tratamiento del sindrome de rett.
WO2017132127A1 (en) 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
WO2018217766A1 (en) * 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
CN108187031A (zh) * 2018-02-11 2018-06-22 中国人民解放军第四军医大学 rhIGF1在制备治疗脆性X综合征药物中的应用
CA3153776A1 (en) 2019-09-09 2021-03-18 The University Of Chicago Combination therapy for the treatment of migraines
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤
WO2022055045A1 (ko) * 2020-09-08 2022-03-17 주식회사 선마린바이오테크 콜라게나제 저해 활성 펩타이드 유도체 및 이의 용도
US20240148835A1 (en) * 2021-01-28 2024-05-09 University Of Florida Research Foundation, Incorporated Treating disorders associated with dyrk1a dysfunction

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
CA2114251C (en) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
EP0735894A4 (en) * 1993-12-23 1999-08-18 Auckland Uniservices Ltd COMPOSITION AND METHODS FOR IMPROVING THE OUTCOME OF NERVOUS SYSTEM CONDITIONS
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US20020132252A1 (en) * 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1109572A4 (en) * 1998-09-03 2004-11-24 Neuronz Ltd NEUROPROTECTION
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
WO2002057241A1 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2002056873A2 (en) 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
JP4489352B2 (ja) * 2001-02-09 2010-06-23 ジェネンテック， インコーポレイテッド Ｉｇｆ−１の結晶化
ES2325983T3 (es) * 2001-05-24 2009-09-28 Neuren Pharmaceuticals Limited Analogos y peptidomimeticos de gpe.
US7863304B2 (en) * 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1648873A4 (en) * 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE MACROCYLIC COMPOUNDS AND METHODS OF THEIR APPLICATION
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
EP1667521B1 (en) * 2003-09-12 2011-12-07 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
EP1684783A4 (en) * 2003-10-23 2009-07-08 Neuren Pharmaceuticals Ltd NEUROPROTECTIVE EFFECTS OF GLY-PRO-GLU AFTER INTRAVENOUS INFUSION
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
CN101022820A (zh) * 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置
KR20060040550A (ko) * 2004-11-05 2006-05-10 마루이시세이야쿠가부시키가이샤 인슐린유사 성장인자-1 분비촉진제
EP1901770B1 (en) 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
CA2650140A1 (en) * 2006-04-14 2007-10-25 Mriganka Sur Identifying and modulating molecular pathways that mediate nervous system plasticity

Also Published As

Publication number Publication date
US20090099077A1 (en) 2009-04-16
EP2164509A1 (en) 2010-03-24
AU2008262387A1 (en) 2008-12-18
CA2689549A1 (en) 2008-12-18
WO2008153929A1 (en) 2008-12-18
CN101820896A (zh) 2010-09-01
US20120177630A1 (en) 2012-07-12
JP2010529128A (ja) 2010-08-26
US7994127B2 (en) 2011-08-09

Similar Documents

Publication Publication Date Title
BRPI0812768A2 (pt) Igf para o tratamento de síndrome de rett e transtornos sinápticos.
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0915282A2 (pt) agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
PT2240137T (pt) Aparelho para o tratamento da obesidade
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BR112012002578A2 (pt) composição para o tratamento da fibrose cística
BRPI0916756A2 (pt) sistemas e métodos para anestesiar o tecido auricular.
BRPI1010868A2 (pt) terapia gênica para distúrbios neurodegenerativos
BRPI0920334A2 (pt) métodos para o tratamento de distúrbios pulmonares com formulações de amicacina lipossomal.
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
PT2894165T (pt) Métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0908715A2 (pt) métodos para tratamento da psoríase
PT2501234T (pt) Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.